Aktie A3D76S BIONEXUS GENE LAB CORP.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen BioNexus Gene Lab Corp.

Aktien

A3D76S

US0906282076

BGLC

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 26.04.2024 		% 5 Tage % 1. Jan.
0,5935 USD +0,15 % Intraday Chart für BioNexus Gene Lab Corp. -1,05 % +11,98 %
16.04. BioNexus Gene Lab Corp. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
29.02. BioNexus Gene Lab Corp. Informiert seine Aktionäre CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare
BioNexus Gene Lab : Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare - Form 8-K
BioNexus Gene Lab Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
BioNexus Gene Lab : Submission of Matters to a Vote of Security Holders - Form 8-K
BioNexus Gene Lab Corp. Provides Information to Shareholders
Certain Common Stock of BioNexus Gene Lab Corp. are subject to a Lock-Up Agreement Ending on 18-JAN-2024.
Soo Kow Lai Provides Information to Shareholders of BioNexus Gene Lab Corp
BioNexus Gene Lab Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Bionexus Gene Lab Corp. Announces Resignation of Wei Li Leong as Chief Financial Officer
BioNexus Gene Lab Names Chi Yuen Leong as CEO
BioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as the Chief Executive Officer
BioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as A Director
BioNexus Gene Lab Corp. Announces Resignation of Sook Keng Yeoh as Chief Executive Officer
BioNexus Gene Lab Corp. Announces Resignation of Sook Keng Yeoh as Board of Directors
BioNexus Gene Lab Corp. Announces Executive Changes
Top Premarket Gainers
BioNexus Gene Lab Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
BioNexus Gene Lab Raises $5.8 Million from Public Share Offering
BioNexus Gene Lab Corp. Announces Closing of $5.75 Million Public Offering and Full Exercise of Over-Allotment Option and Uplisting to the Nasdaq Capital Market
BioNexus Gene Lab Corp.(NasdaqCM:BGLC) added to NASDAQ Composite Index
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3D76S Aktie
  4. Nachrichten BioNexus Gene Lab Corp.
  5. Andere Sprachen